Urica Therapeutics, founded in 2021 and based in Cambridge, USA, was established to develop dotinurad for gout and hyperuricemia. In a significant strategic shift in July 2024, the company transferred all rights to dotinurad and related IP to Crystalys Therapeutics. As of late 2025, Urica appears to be an inactive shell entity with no disclosed pipeline or ongoing operations, serving primarily as a legacy subsidiary of Fortress Biotech.
GoutHyperuricemiaMetabolic Disorders
Funding History
2
Total raised:$2.3M
Grant$500KNational Institutes of Health
Seed$1.8MUndisclosed
Opportunities
The primary opportunity was the development of dotinurad, a potential best-in-class URAT1 inhibitor for the large and growing gout market.
This opportunity is now held by Crystalys Therapeutics.
For Urica/Fortress, the opportunity lies in potential future financial returns from the asset sale agreement with Crystalys.
Risk Factors
Urica faces existential risk as a dormant shell company with no active operations or pipeline.
Its value is entirely contingent on the success of dotinurad in Crystalys's Phase 3 trials and subsequent commercialization, which carries significant clinical, regulatory, and competitive risks.
Competitive Landscape
The gout treatment market is competitive, featuring generic xanthine oxidase inhibitors (allopurinol), branded XOIs (febuxostat), URAT1 inhibitors (probenecid, lesinurad), and uricase therapies. Dotinurad aims to compete by offering improved safety and once-daily dosing within the URAT1 inhibitor class.
